PMID- 19922469
OWN - NLM
STAT- MEDLINE
DCOM- 20100201
LR  - 20220225
IS  - 1742-4658 (Electronic)
IS  - 1742-464X (Linking)
VI  - 277
IP  - 2
DP  - 2010 Jan
TI  - Epidermal growth factor receptor in relation to tumor development: EGFR gene and 
      cancer.
PG  - 301-8
LID - 10.1111/j.1742-4658.2009.07448.x [doi]
AB  - Epidermal growth factor receptor (EGFR) and its three related proteins (the ERBB 
      family) are receptor tyrosine kinases that play essential roles in both normal 
      physiological conditions and cancerous conditions. Upon binding its ligands, 
      dynamic conformational changes occur in both extracellular and intracellular 
      domains of the receptor tyrosine kinases, resulting in the transphosphorylation 
      of tyrosine residues in the C-terminal regulatory domain. These provide docking 
      sites for downstream molecules and lead to the evasion of apoptosis, to 
      proliferation, to invasion and to metastases, all of which are important for the 
      cancer phenotype. Mutation in the tyrosine kinase domain of the EGFR gene was 
      found in a subset of lung cancers in 2002. Lung cancers with an EGFR mutation are 
      highly sensitive to EGFR tyrosine kinase inhibitors, such as gefitinib and 
      erlotinib. Here, we review the discovery of EGFR, the EGFR signal transduction 
      pathway and mutations of the EGFR gene in lung cancers and glioblastomas. The 
      biological significance of such mutations and their relationship with other 
      activated genes in lung cancers are also discussed.
FAU - Mitsudomi, Tetsuya
AU  - Mitsudomi T
AD  - Department of Thoracic Surgery, Pathology and Molecular Diagnostics, Aichi Cancer 
      Center Hospital, Nagoya, Japan. mitsudom@aichi-cc.jp
FAU - Yatabe, Yasushi
AU  - Yatabe Y
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20091118
PL  - England
TA  - FEBS J
JT  - The FEBS journal
JID - 101229646
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (KRAS protein, human)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - Colorectal Neoplasms/drug therapy/genetics
MH  - Drug Resistance, Neoplasm/genetics
MH  - ErbB Receptors/antagonists & inhibitors/*genetics/*physiology
MH  - Humans
MH  - Lung Neoplasms/drug therapy/genetics
MH  - Models, Biological
MH  - Mutation
MH  - Neoplasms/*drug therapy/etiology/*genetics
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Proto-Oncogene Proteins/genetics
MH  - Proto-Oncogene Proteins p21(ras)
MH  - ras Proteins/genetics
RF  - 34
EDAT- 2009/11/20 06:00
MHDA- 2010/02/02 06:00
CRDT- 2009/11/20 06:00
PHST- 2009/11/20 06:00 [entrez]
PHST- 2009/11/20 06:00 [pubmed]
PHST- 2010/02/02 06:00 [medline]
AID - EJB7448 [pii]
AID - 10.1111/j.1742-4658.2009.07448.x [doi]
PST - ppublish
SO  - FEBS J. 2010 Jan;277(2):301-8. doi: 10.1111/j.1742-4658.2009.07448.x. Epub 2009 
      Nov 18.